Associate Professor Richard Benninger and his lab recently published a research article in Nature Communications “Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type 1 diabetes progression in preclinical models”. Non-invasive techniques to assess the progression of type 1 diabetes prior to clinical onset are needed, both for disease diagnosis and for monitoring the efficacy of therapeutic reversal. The Benninger lab applied a contrast-enhanced ultrasound measurement of mouse pancreatic blood flow to detect changes in the islet microvasculature that undergoes rearrangements during diabetes. These measurements predicted both rapid disease progression as well as the success of therapeutic interventions to reverse disease progression. This study is particularly significant as both the widespread deloyment of ultrasound modalities and the clinical approval of ultrasound contrast agents will facilitate clinical translation for monitoring disease progression in populations at risk for type1 diabetes. This study was primarily supported by funding from the JDRF and NIH, and lead author Josh St Clair was funded by the “Cardiovascular Imaging and Biomechanics” T32 training program and an F32 NRSA postdoctoral fellowship.
Assistive Technology Partners (ATP) is deeply grateful for the ongoing support from the Colorado construction industry’s annual Déjà vu Rendezvous event. Held May 18, 2018, this eleventh event offered a chance to unite past and current members of the Colorado construction community while supporting a worthwhile cause. Proceeds from the event help ATP, housed in the Department of Bioengineering, meet their mission for persons with cognitive, sensory, and/or physical disabilities to reach their highest potential at home, school, work and play through the addition of appropriate assistive technologies to their lives. This year the event hosted 800 guests at Denver’s Mile High Station and brought cumulative donations to more than $2.3M.
The event created by retired Trautman & Shreve CEO, Bill Caile, is sponsored by more than 100 corporations.
Cathy Bodine, executive director of ATP and associate professor of bioengineering, says, “We are so grateful to the local construction companies and our generous sponsors for choosing ATP to benefit from such a wonderful annual event.” Funds will be used to support persons with disabilities, their families and others who are unable to afford services.
“The Déjà-vu event has always been focused on the wonderful people that make up the construction industry in Colorado and the relationships we all have,” says Marc Able, Steering Committee Chair and President, ABLE Consulting Group, LLC.. “It is one night a year where we leave the business at the door and celebrate everyone on a personal level. It is such a fun night and to be able to support the great work ATP does is icing on the cake.”
Matthew Davidson, a postdoctoral fellow in Dr Bodine’s lab, was selected as a delegate for the American Society of Biochemistry and Molecular Biology’s Advocacy Training Program. This externship will train Dr. Davidson to be an advocate for the life sciences at the federal and state level. This will provide him the tools to effect policy change and support science funding.